Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more
Cellumed Co. Ltd - Asset Resilience Ratio
Cellumed Co. Ltd (049180) has an Asset Resilience Ratio of 1.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Cellumed Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cellumed Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.14 Billion | 1.6% |
| Total Liquid Assets | ₩1.14 Billion | 1.60% |
Asset Resilience Insights
- Limited Liquidity: Cellumed Co. Ltd maintains only 1.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cellumed Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Cellumed Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931 |
Medical Instruments & Supplies | 0.06% |
|
Blue Sail Medical Co Ltd
SHE:002382 |
Medical Instruments & Supplies | 5.12% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 35.75% |
|
Allmed Medical Products Co Ltd Class A
SHE:002950 |
Medical Instruments & Supplies | 3.78% |
|
Inix Technologies Holdings Bhd
KLSE:0094 |
Medical Instruments & Supplies | 0.06% |
|
Focus Point Holdings Bhd
KLSE:0157 |
Medical Instruments & Supplies | 2.30% |
|
Careplus Group Bhd
KLSE:0163 |
Medical Instruments & Supplies | 4.91% |
|
LKL International Bhd
KLSE:0182 |
Medical Instruments & Supplies | 0.38% |
Annual Asset Resilience Ratio for Cellumed Co. Ltd (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Cellumed Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | ₩34.26 Million | ₩70.22 Billion | -0.88pp |
| 2023-12-31 | 0.93% | ₩619.54 Million | ₩66.47 Billion | -9.96pp |
| 2022-12-31 | 10.90% | ₩10.16 Billion | ₩93.26 Billion | -15.10pp |
| 2021-12-31 | 25.99% | ₩25.05 Billion | ₩96.37 Billion | -6.39pp |
| 2020-12-31 | 32.38% | ₩22.93 Billion | ₩70.80 Billion | -0.31pp |
| 2019-12-31 | 32.69% | ₩21.24 Billion | ₩64.98 Billion | +16.18pp |
| 2018-12-31 | 16.51% | ₩8.18 Billion | ₩49.58 Billion | +13.02pp |
| 2017-12-31 | 3.48% | ₩2.26 Billion | ₩64.98 Billion | -5.63pp |
| 2016-12-31 | 9.11% | ₩6.36 Billion | ₩69.79 Billion | +5.37pp |
| 2015-12-31 | 3.74% | ₩3.07 Billion | ₩82.00 Billion | +2.85pp |
| 2014-12-31 | 0.88% | ₩622.65 Million | ₩70.40 Billion | -0.83pp |
| 2013-12-31 | 1.72% | ₩1.34 Billion | ₩77.78 Billion | +0.71pp |
| 2012-12-31 | 1.01% | ₩835.60 Million | ₩82.59 Billion | -2.32pp |
| 2011-12-31 | 3.33% | ₩2.64 Billion | ₩79.25 Billion | +2.97pp |
| 2008-12-31 | 0.37% | ₩230.00 Million | ₩62.32 Billion | -- |